response to pegylated interferon plus ribavirin in patients with hepatitis c virus genotype 6a infection from guangdong and guangxi province of china

Clicks: 156
ID: 224286
2016
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #151 of 188 articles by views in colloids and surfaces a: physicochemical and engineering aspects

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 188 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Aim. Our aim is to survey the treatment effect of PEG-IFN plus ribavirin in patients infected with HCV genotype 6a in Guangdong and Guangxi province of China and investigate best course of antiviral treatment for patients with HCV-6a infection. Methods. 515 eligible patients received subcutaneous 180 μg PEG-IFNα-2a or 1.5 μg/kg PEG-IFNα-2b once weekly plus oral ribavirin. Primary outcome was SVR by intention-to-treat analysis. Secondary outcome was RVR, cEVR, ETR, and relapse rate. Results. SVR in patients with HCV-6a infection treated for 48 weeks was comparable to that in patients with HCV-2/3 infection (80.9% versus 82.5%, p=0.812) and higher than that in patients with HCV-1b infection (80.9% versus 67.2%, p=0.014). ETR (98.9% versus 90.6%, p=0.016), virological response at month 3 of end-of- treatment (88.8% versus 76.6%, p=0.044), SVR (80.9% versus 65.6%, p=0.032), and virological response at month 12 of end-of-treatment (76.4% versus 60.9%, p=0.04) in patients with HCV-6a infection treated for 48 weeks were higher than those in patients with HCV-6a infection treated for 24 weeks. Conclusion. SVR in patients with HCV-6a treated for 48 weeks was comparable to that in patients with HCV-2/3 infection and higher than that in patients with HCV-1b infection; patients with HCV-6a infection treated for 48 weeks had a superior treatment response than patients treated for 24 weeks.
Reference Key
tong2016gastroenterologyresponse Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Wangxia Tong, Jianyun Zhu, Ning Luo, Xiaohua Yang, Zhiying Lei, Xiaoliang Huang, Zhixin Zhao, Xiaohong Zhang, Zhiliang Gao, Zhonghua Jiang
Are you one of these authors? Claim your profile
Journal colloids and surfaces a: physicochemical and engineering aspects
Year 2016
DOI
10.1155/2016/5397407
URL
http://dx.doi.org/10.1155/2016/5397407
Keywords
Gastroenterology diseases of the digestive system

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.